RAHWAY, N.J. — Merck Animal Health announces it has signed a definitive agreement to obtain TARGAN, a privately held company that specializes in developing biodevice technologies designed to improve poultry performance.
This acquisition is for an undisclosed amount; however, Merck has been an investor in TARGAN for the past 9 years and has been one of the company’s largest shareholders. Officials note that contingent upon regulatory approval and additional closing conditions, the purchase is anticipated to be completed in the third quarter of this year.
“The acquisition of TARGAN’s best-in-class biodevice technology for use. . .
Register or Login to keep reading
Thank you for your interest in accessing the complete content. To continue reading, please register for free. By registering, you'll gain full access to our valuable resources, updates, and insights.
If you already have an account please Log In.
